The Cosmetics & Personal Care Testing division of Eurofins, a provider of sunscreen cosmetics and personal care testing, offers a comprehensive range of testing and clinical services in Europe, North America, Asia-Pacific and Africa.
As part of its strategy to reinforce its global leadership in cosmetics and personal care and to diversify its clinical trial offering in dermatology, drugs and medical devices, Eurofins announces that it has successfully completed the acquisition of bioskin, a German specialist in testing for drugs, medical devices, food supplements and cosmetics.
Over the past 30 years, bioskin has built up a reputation for excellence in conducting dermatology clinical trials for drugs and medical devices. The company employs over 60 people at its Hamburg site, and generated sales of over €11 million in 2020. Bioskin brings to Eurofins innovative capabilities, a strong position in early phase studies and proof-of-concept models, international multicenter phase II-III studies, as well as unique expertise with its own in-house research center.
With this acquisition, Eurofins intends to offer a range of complementary services, support its growth and diversify its offering and capabilities to provide its customers with access to multi-center studies.
Gilles Martin, CEO of Eurofins, said: "Cosmetics, suncare and personal care products have an impact on our health and well-being. Manufacturers active in these fast-growing sectors are constantly innovating to develop better products for consumers and patients. So today we're very excited to be partnering with bioskin and broadening and deepening the range of tests and quality of service we can offer our customers in the development of cosmetics, personal care and dermatology products."
Photo credit : Pixabay
